**PHARMACOLOGIC TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS**

**Beverly G. Tchang, MD,** Assistant Professor of Clinical Medicine, Division of Diabetes, Endocrinology, and Metabolism, Weill Cornell Medical College, New York, NY. E-mail: bgt9001@med.cornell.edu

**Mohini Aras, MD,** Assistant Professor of Clinical Medicine, Division of Diabetes, Endocrinology, and Metabolism, Weill Cornell Medical College, New York, NY

**Rekha B. Kumar, MD, MS,** Associate Professor of Clinical Medicine, Division of Diabetes, Endocrinology, and Metabolism, Weill Cornell Medical College, New York, NY

**Louis J. Aronne, MD,** Sanford I. Weill Professor of Metabolic Research, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medical College, New York, NY

**Updated August 20, 2024**

**ABSTRACT**

Obesity pharmacotherapy has evolved significantly over the past 60 years. Today, six anti-obesity medications (AOMs) are approved by the Federal Drug Administration (FDA) for the long-term treatment of obesity. Similar in approach to other chronic diseases, AOMs are indicated in combination with lifestyle modification for the management of overweight and obesity. Current guidelines recommend that individuals who have attempted lifestyle improvements and continue to have a body mass index (BMI) of ≥ 30 kg/m2 or ≥ 27 kg/m2 with an obesity-related comorbidity are eligible for weight loss medication treatment. The AOMs reviewed in this chapter include the FDA-approved medicines for chronic weight management, FDA-approved medicines for short-term use of weight management, and off-label use of medicines that have demonstrated benefits for weight control.

**INTRODUCTION**

Obesity is recognized as a major pandemic of the 21st century, contributing to increased morbidity, mortality, and the burden of healthcare costs (1). Overweight and obesity are defined by the World Health Organization (WHO) as a BMI of 25-29.9 kg/m2 and a BMI ≥ 30 kg/m2, respectively (2). In the United States, the prevalence of obesity had risen to 42.4% in 2017-2018 (3) and predictive models now suggest that the prevalence will grow to one in two adults by 2030 (4). Internationally, one in five adults now have obesity (5). The Global Burden of Disease study reports that overweight and obesity are the fourth leading risk for global deaths, and more than 4.7 million adults die each year as a result of overweight or obesity (6). Obesity is a major risk factor in the development of cardiovascular disease (CVD), type 2 diabetes (T2D), musculoskeletal disorders, and several cancers (2). In certain ethnic populations (i.e., East Asian or South Asian), these comorbidities can develop at lower BMIs (7).

The associations between obesity, central obesity (increased waist circumference, especially intra-abdominal/visceral fat) and the risks for cardiometabolic diseases as well as obstructive sleep apnea, asthma, and nonalcoholic fatty liver disease (NAFLD) are well established (8,9). Cytokines secreted from visceral adipocytes, including interleukin-6, tumor necrosis factor alpha, resistin, and plasminogen activation inhibitor-1, have been implicated in the pathogenesis of these diseases, in part by promoting local and systemic states of inflammation and thrombosis (10-12). A reduction in body weight of 5-10% significantly lowers inflammatory and pro-thrombotic makers, as well as chronic disease incidence (13,14).

**OBESITY PHARMACOTHERAPY**

**Principles of Obesity Pharmacotherapy**

As with other chronic metabolic diseases, the initial management of overweight and obesity emphasizes sustainable nutritional, physical activity, and behavioral changes that have been shown to reduce weight and lower cardiometabolic risk. However, lifestyle interventions that include caloric restriction and/or portion control alone are insufficient in achieving long-term weight loss maintenance in most patients, with one-third to two-thirds of lost weight regained within one-year following end of treatment, and > 95% weight regained within 5 years (15).

For patients who have failed to achieve clinically significant weight loss, defined as ≥ 5% of baseline weight (16) after 6 months of lifestyle interventions (16-19), professional organizations including The Obesity Society, the Endocrine Society, and the American Association of Clinical Endocrinologists recommend AOMs for individuals with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with comorbidities.

For health care professionals using pharmacotherapy for weight management, the following basic principles can be kept in mind:

* **Lifelong treatment:** Because obesity is a chronic disease, pharmacotherapy should be prescribed with the intent of lifelong use and as part of a comprehensive management plan that includes nutrition, physical activity, and behavioral counseling. Discontinuation of an AOM often leads to weight regain.
* **AOMs affect pathophysiological pathways that lead to obesity:** Current obesity pharmacotherapy targets the underlying neurohormonal dysregulations that cause weight gain and prevent sustained weight loss. Changes in hormones in response to diet-induced weight loss, such as reduction in the anorexigenic hormone leptin and increase in the orexigenic hormone ghrelin, create a physiologic environment conducive to the body returning to its previously established, higher body weight set point (20,21). Additional adaptation responses to diet-induced weight loss affecting energy expenditure, including reductions in basal metabolic rate, also challenge weight loss maintenance (22,23).
* **Treatments benefit both weight and comorbidities:** The goals of obesity treatment are primary, secondary, and tertiary prevention (17); that is, to prevent the development or exacerbation of obesity and its complications. For example, improvements in cardiometabolic risk factors and reduced diabetes risk have been consistently reported in the Phase 3 trials for AOM’s.
* **Expect heterogeneity in weight loss response:** Phase 3 trials have consistently demonstrated that AOMs achieve significantly greater weight loss than placebo when combined with lifestyle modifications (24-31). The average efficacy in these studies ranges from 5-23% total body weight loss. However, as with any medical therapy, significant inter-individual response variability (32,33) has been reported, including the possibility of no weight loss (non-responders) to 25% or greater weight loss.

**History of Anti-Obesity Medications**

The development of AOMs dates as far back as the 1940s, predating the standard FDA rules and regulations that are familiar today. Drug approval in the 1940s necessitated only proof of efficacy beyond placebo; evaluation of benefit versus risk with controlled investigations was not a requirement until passage of the Kefauver-Harris amendment in 1962. Approval of the first AOM, desoxyephedrine, in 1947 led to the development of a number of amphetamine derivatives for weight loss that have all since been removed from the market due to this amendment (34). A comprehensive narrative of the history of AOMs covers the development of pharmacotherapy and the FDA’s role in regulation (35). Since the FDA’s adoption of stricter regulations and proof of *clinical* efficacy, only a couple of AOMs have been removed from the U.S. market for safety concerns (Table 1).

|  |
| --- |
| **Table 1. Selected Historical Anti-Obesity Medications** |
| **Name (Trade Name)** | **Years Approved** | **Reason for Removal** |
| Sibutramine (Meridia) | 1997-2010 | Patients at high risk for CVD were found to have elevated risk of CVD events when given sibutramine (36) |
| Lorcaserin (Belviq) | 2012-2020 | Re-analysis of a safety clinical trial showed an increased incidence of certain cancers (37) |

Only two AOMs have been removed from the market in recent history. The administration of sibutramine to individuals at high risk of CVD in the SCOUT trial was widely criticized by the medical community as it did not reflect real-life clinical practice; subgroup analysis of patients with T2D without CVD in SCOUT actually showed no increase in CVD events and a decrease in mortality with sibutramine compared to placebo (38). The voluntary recall of lorcaserin in 2020 occurred among significant confusion, as long-term data from the CAMELLIA-TIMI 61 trial did not demonstrate an imbalance in adverse events between treatment groups (39,40). The FDA has clarified their findings that led to this withdrawal recommendation. When all post-randomization adverse events were considered, not just those that occurred “on treatment” (i.e., those that occurred within 30 days of drug discontinuation) as analyzed in CAMELLIA-TIMI 61 (37), even though similar numbers of patients experienced cancers (n=462 out of 6000 on lorcaserin and n=423 out of 6000 on placebo), a greater number of participants who received lorcaserin compared to placebo were reported with multiple primary cancers (n=20 vs. 8), total cancers (n=520 vs. 470), metastases (n=34 vs. 19), and cancer deaths (n=52 vs. 33). The latency period to reach significance for differences in all cancers between the treatment groups was a little over 2 years, and although the overall cancer rates were low, the FDA felt that benefits of lorcaserin could not yet be judged to outweigh this adverse risk.

**FDA-Approved Medications for Weight Management**

Today, nine FDA-approved AOMs remain on the market, with six approved for long-term weight loss, of which one is indicated for specific monogenic obesity mutations, and one “device” that functions as a medication (Table 2).

|  |
| --- |
| **Table 2. FDA Approved Anti-Obesity Medications** |
| **Name (Trade Names)** | **Year Approved** | **Mechanism of Action / Clinical Effect** | **Average placebo-subtracted weight loss (%)** | **Achieved ≥5% Weight Loss, Intervention vs. placebo (%)** |
| *Approved for short-term use\** |
| Phentermine (Adipex, Lomaira) (41) | 1959 | Sympathomimetic / Suppresses appetite | 4.4 at 28 wks | 49 vs.16 at 28 wks |
| Diethylpropion (42) | 197 1979 | Sympathomimetic / Suppresses appetite | 6.6 at 6 months | 67.6 vs. 25.0 |
| *Approved for long-term use* |
| Orlistat (Alli, Xenical) (43) | 1999 | Intestinal lipase inhibitor / Reduces fat absorption by up to 30% | 3.8 | 50.5 vs. 30.7 |
| Phentermine-topiramate (Qsymia) (26) | 2012 | Combination sympathomimetic and carbonic anhydrase inhibitor / Decreases appetite and binge eating behaviors | 8.6 | 70 vs. 21 |
| Bupropion-naltrexone (Contrave) (44) | 2014 | Combination of a dopamine and norepinephrine re-uptake inhibitor and mu-opioid receptor antagonist / Decreases appetite and cravings | 4.8 | 48 vs. 16 |
| Liraglutide 3.0mg (Saxenda) (28) | 2014 | GLP-1 receptor agonist / Decreases appetite, increases fullness, increases satiety | 5.4 | 63.2 vs. 27.1 |
| Gelesis100 (Plenity) (45)  | 2019 | Superabsorbent hydrogel particles of a cellulose-citric acid matrix / Increases fullness. Considered a medical device but functions as a medication. | 2.0 at 6 months | 58.6 vs. 42.2 |
| Setmelanotide (Imciveree) | 2020 | Melanocortin-4-receptor agonist / Decreases appetite | Not applicable12.5-25.6† | Not applicable64-90† |
| Semaglutide 2.4 mg (Wegovy) | 2021 | GLP-1 receptor agonist / Decreases appetite, increases fullness, increases satiety | 12.4 | 86.4 vs. 31.5 |
| Tirzepatide (Zepbound) | 2023 | GLP-1 and GIP receptor agonist / Decreases appetite, increases fullness, increases satiety | 17.8 | 91 vs 35 |

Weight loss outcomes reported are based on intention-to-treat or intention-to-treat last observation carried forward analyses from RCTs using the maximum doses of medications for 56 weeks unless otherwise stated (17). GLP-1, glucagon-like peptide-1. GIP, glucose-stimulated insulinotropic peptide. \*Short-term use is generally accepted as 3 months. †Range of weight loss observed in single-arm trial (not placebo-controlled) depended on genetic mutation.

**PHENTERMINE AND DIETHYLPROPION**

Phentermine (trade name Adipex) was among the first FDA-approved short-term medications for weight loss and remains available today. Phentermine is a sympathomimetic anorexigenic agent. A study from 1968 is the only longer-term controlled trial of phentermine (46). In this 36-week study, 64 patients were randomized to placebo, phentermine 30 mg daily, or intermittent phentermine 30 mg daily (4 weeks on, 4 weeks off). Both phentermine groups lost approximately 13% of their initial weight, while the placebo group lost only 5%. As discussed below, phentermine in combination with topiramate has been approved for long-term use.

[Diethylpropion](http://www.uptodate.com/contents/diethylpropion-drug-information?source=see_link) (trade name Tenuate), another sympathomimetic and derivative of bupropion, is also an approved *short-term* drug for treating obesity. It acts through modulation of norepinephrine action. A 6-month double-blinded placebo-controlled RCT followed by an open-label 6-month extension in 69 adults with obesity demonstrated diethylpropion 50 mg twice a day resulted in average weight loss of 9.8% at 6 months vs. 3.2% with placebo (42).

Phentermine’s and diethylpropion’s main side effects are related to their sympathomimetic properties, including elevation in blood pressure and pulse, insomnia, constipation, and dry mouth (47). Sympathomimetic agents are contraindicated in individuals with uncontrolled hypertension, known CVD (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure), hyperthyroidism, glaucoma, or exposure to monoamine oxidase inhibitors during or within 14 days of administration. Caution should be used in patients with pulmonary hypertension.

**ORLISTAT**

Orlistat (trade name Xenical) is approved for adult and adolescent obesity (ages 12 to 16) (48). It promotes weight loss by inhibiting gastrointestinal lipases, thereby decreasing the absorption of fat from the gastrointestinal tract. On average, 120 mg of orlistat taken three times per day will decrease fat absorption by 30% (49). Orlistat has been found to be more effective in inhibiting the digestion of fat in solid foods, as opposed to liquids (50). Orlistat at a lower dose of 60 mg 3 times daily (trade name Alli) is approved for over-the-counter use in the United States (51).

**Efficacy**

Several trials support orlistat’s efficacy for weight loss and maintenance. Rossner et al. found that subjects receiving orlistat lost significantly more weight in the first year of treatment, and fewer regained weight during the second year of treatment, than those taking placebo (52). Subjects taking orlistat had significantly lower serum levels of vitamins D, E, and B-carotene. However, these nutritional deficiencies are easily treated with oral multivitamin supplementation. Trials in Europe demonstrated similar results over a two-year period. Subjects in the orlistat group lost significantly more weight in the first year (10.2 vs. 6.1%) and regained half as much weight during the second year of treatment, as compared to the placebo group (53).

**Effect on Metabolic Profile**

In addition to promoting weight loss and maintaining lost weight, orlistat has been shown to improve insulin sensitivity and lower serum glucose levels. In a 2-year trial, Davidson et al. reported less weight regain rates and lower levels of serum glucose and insulin in patients maintained on a 120 mg three times per day dose of orlistat, as compared to those on placebo (54). In the 4-year XENDOS study conducted in Sweden, the cumulative incidence of T2D was 9.0% in the placebo plus diet and lifestyle group and 6.2% in the subjects receiving orlistat (24), corresponding to a risk reduction in development of T2D of 37.3%.

In patients with obesity and T2D with or without insulin treatment, orlistat resulted in improved glycemic control, determined via serum blood glucose levels and hemoglobin A1c (HbA1c) measurements, and reduced total cholesterol, low density lipoprotein (LDL) cholesterol, triglyceride, and apolipoprotein B levels (55,56). In subjects with obesity and T2D, hypercholesterolemia, or hypertension, orlistat treatment also led to greater weight loss and reductions in HbA1c, LDL, and total cholesterol (57).

**Safety and Side-Effects**

The gastrointestinal side effects of orlistat, including fatty/oily stool, fecal urgency, oily spotting, increased defecation, fecal incontinence, flatus with discharge, and oily evacuation (48), are the main reasons for discontinuation of therapy. These symptoms are usually mild to moderate and decrease in frequency the longer the medication is continued. Administration of orlistat with psyllium mucilloid reduced the incidence of GI side effects to 29% with psyllium vs. 71% without psyllium (58). Orlistat may reduce the absorption of fat-soluble vitamins A, D, E, and K, which can be mitigated with separate administration of vitamin supplementation.

**PHENTERMINE/TOPIRAMATE**

The controlled-release, single-tablet combination phentermine plus topiramate (trade name Qsymia) was approved by the FDA in 2012 as a long-term treatment for obesity for adults with BMI ≥ 30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity. Phentermine is thought to promote weight loss by increasing norepinephrine release and decreasing its uptake in hypothalamic nuclei, leading to a decrease in food intake (59). It also acts as an adrenergic agonist that activates the sympathetic nervous system (60) to possibly increase energy expenditure. Topiramate is an FDA-approved medicine for epilepsy and migraine prophylaxis that has been shown to reduce body weight by promoting taste aversion and decreasing caloric intake (61). A carbonic-anhydrase inhibitor, topiramate was found to stimulate lipolysis in preclinical studies (62). Phentermine/topiramate is available in 4 doses: 3.75/23 mg (starting dose), 7.5/46 mg (lowest treatment dose), 11.25/69 mg or 15/92 mg (maximum treatment dose) daily.

**Efficacy**

Multiple Phase 1, 2, and 3 studies including more than 5000 subjects have evaluated the efficacy and safety of phentermine/topiramate combination therapy. The one-year EQUIP trial, a phase three 56-week RCT enrolled 1267 patients with obesity (mean BMI of 42.0 kg/m2) and showed 3.5% weight loss in the starting dose group (3.75 mg/23 mg) and 9.3% placebo-subtracted weight loss in the top treatment dose (15 mg/92 mg) group (27). The 52-week CONQUER trial randomized 2487 patients with obesity and a comorbidity (e.g. hypertension, dyslipidemia, prediabetes, diabetes, or abdominal obesity) to placebo, mid-dose treatment dose (7.5mg/46 mg), or maximum treatment dose (15/92 mg) and found 6.6% and 8.6% placebo-subtracted weight loss in the mid and maximum dose arms, respectively (26). A two-year extension of the CONQUER trial was published (SEQUEL) demonstrating mean placebo-subtracted weight loss of 7.5% in the mid-dose group and 8.7% in the maximum-dose group (63).

**Effect on Metabolic Profile**

Improvements in systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides, and high-density lipoprotein (HDL) cholesterol were seen in subjects treated with phentermine plus topiramate compared with placebo in both EQUIP and CONQUER (26,27). Improvements in fasting glucose and insulin levels were seen in the SEQUEL study, and a 54% and 76% reduction in progression to T2D in the two treatment groups was noted in subjects without diabetes at baseline (63).

**Safety and Side Effects**

Phentermine-topiramate is not recommended for patients with significant cardiac history such as coronary disease and uncontrolled hypertension (64). However, in individuals without coronary disease and with well-controlled hypertension, it is considered safe to use this drug along with regular blood pressure monitoring. Phentermine/topiramate exposure carries an increased risk of cleft lip/palate in infants exposed to the combination drug during the first trimester of pregnancy. Women of child-bearing age should have a pregnancy test prior to starting the medicine and be using contraception while taking it. Clinicians who prescribe phentermine-topiramate and pharmacists who dispense it should enroll in a Risk Evaluation and Mitigation Strategy (REMS), which includes education on prescribing information, monitoring during treatment, and side effects. This medication is also contraindicated in patients with hyperthyroidism, glaucoma, and in patients who have taken monoamine oxidase (MAO) inhibitors within 14 days. Topiramate can increase the risk of acidosis and renal stones so should be used cautiously in patients who have had stones previously (65).

In order to mitigate side effects, which include paresthesias, dizziness, dry mouth, constipation, dysgeusia, insomnia, and anxiety, a step-wise dosage titration is recommended. Phentermine-topiramate is initiated at the 3.75/23 mg dose daily for 14 days, followed by 7.5/46 mg daily thereafter. If after 12 weeks, a 3 percent loss in baseline bodyweight is not achieved, the dose can be increased to 11.25/69 mg for 14 days, and then to 15/92 mg daily. If an individual does not lose 5 percent of body weight after 12 weeks on the highest dose, phentermine-topiramate should be discontinued due to lack of response. Discontinuation should be performed gradually because rapid withdrawal of topiramate may provoke seizures.

**BUPROPION/NALTREXONE**

The combination tablet of bupropion and naltrexone (trade name Contrave) was FDA-approved for weight loss in September 2014. Bupropion is a reuptake inhibitor of dopamine and norepinephrine that promotes activation of the central melanocortin pathways (66). Naltrexone is an opioid receptor antagonist that diminishes the mu-opioid receptor auto-inhibitory feedback loop on anorexigenic hypothalamic neurons activated by bupropion, thereby allowing for sustained weight loss (67). Bupropion/naltrexone comes in tablets containing 90 mg of bupropion HCl sustained-release and 8 mg of naltrexone HCl. The recommended starting dose is 1 tablet daily and increasing by 1 tablet each week until a total dose of 2 tabs twice daily is reached (total daily dose: bupropion 360 mg/naltrexone 32 mg).

**Efficacy**

Four 56-week multicenter, double-blind, placebo-controlled trials (CONTRAVE Obesity Research: COR-I, COR-II, COR-BMOD, and COR-Diabetes) were conducted to evaluate the effect of bupropion/naltrexone in conjunction with lifestyle modification compared to a placebo-controlled cohort of 4536 patients. The COR-I, COR-II, and COR-BMOD trials enrolled patients with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one comorbidity (25,30,44). The COR-Diabetes trial enrolled patients with BMI greater than 27 kg/m² with T2D with or without hypertension or dyslipidemia (68). The primary endpoints were percent change from baseline body weight and the proportion of patients achieving at least a 5% reduction in body weight. In the 56-week COR-I trial, significantly greater mean weight loss (6.1%) occurred in patients assigned to naltrexone 32 mg/bupropion 360 mg dose compared with the placebo group (1.3%), and 48% of active treatment group achieved ≥5% weight loss compared to only 16% of placebo group (44). Similar weight loss efficacy was reported in COR-II (25) and COR-Diabetes (68) trials. Bupropion/naltrexone can be combined with intensive behavioral therapy (IBT) to achieve even greater weight loss (5.2% with placebo and 9.3% with bupropion/naltrexone) (30).

**Effect on Metabolic Profile**

In all of the COR trials, secondary cardiovascular risk endpoints were met, including statistically significant greater improvements in waist circumference (WC), visceral fat, HDL cholesterol, and triglyceride levels in the participants treated with the bupropion 360 mg/naltrexone 32 mg dose compared with placebo-treated participants (25,30,44,68). Participants with diabetes in the COR-Diabetes trial using bupropion/naltrexone also showed a significantly greater 0.6% reduction in HbA1c from baseline, compared to a 0.1% reduction in placebo (68).

**Safety and Side Effects**

The most common side effects of bupropion/naltrexone include nausea/vomiting, constipation, headache, dizziness, insomnia, and dry mouth. Medication interactions include MAO inhibitors (use during or within 14 days of administration), opioids and opioid agonists (including partial agonists) that are inactive in the presence of naltrexone, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs that can increase risk for seizure. Bupropion/naltrexone should be avoided in patients with uncontrolled hypertension, history of seizures, history of bulimia or anorexia nervosa, and in individuals taking narcotics for pain control (69).

The FDA recommends monitoring patients for worsening or emergence of suicidal thoughts or behaviors. Women of child-bearing age should have a pregnancy test prior to starting the medicine and be using contraception while taking it.

**LIRAGLUTIDE 3.0**

Liraglutide 3.0 mg (trade name Saxenda) was approved by the FDA in December 2014 for adult obesity and has proven efficacy in adolescents age 12 to <18 years of age (70). Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that activates the GLP-1 receptor. In animal studies, peripheral administration of liraglutide results in uptake in specific brain regions regulating appetite, including the hypothalamus and brainstem (71). A short-term study (5 weeks) involving individuals with obesity and without diabetes demonstrated that liraglutide 3.0 mg/d suppressed acute food intake, subjective hunger, and delayed gastric emptying (72). Energy expenditure in subjects treated with liraglutide 3.0 mg/d decreased, even when corrected for weight loss (72), which may reflect metabolic adaptation to weight loss.

**Efficacy**

SCALE Obesity and Prediabetes (n=3731) and SCALE Diabetes (n=846) evaluated the effect of liraglutide 3.0 mg on overweight and obesity with normoglycemia, prediabetes, and diabetes respectively (28,73). Both 56-week, randomized, placebo-controlled, double-blind clinical trials demonstrated significantly greater mean weight loss than placebo (8% vs. 2.6% in SCALE Obesity and Prediabetes (28) and 6.0% vs. 2% in SCALE Diabetes (73). The efficacy of liraglutide 3.0 in maintaining weight loss was examined in the SCALE Maintenance study. Four hundred and twenty-two subjects who lost ≥ 5% of their initial body weight on a low-calorie diet were randomly assigned to liraglutide 3.0 mg daily or placebo for 56 weeks. Mean weight loss on the initial diet was 6.0%. By the end of the study, participants in the liraglutide 3.0 group lost an additional 6.2% compared to 0.2% with placebo (74).

**Effect on Metabolic Profile**

Secondary endpoints in the SCALE Obesity and Prediabetes included waist circumference, lipids, HbA1c, and blood pressure, all of which showed significantly greater improvement than placebo (28). SBP dropped by 4.2 mmHg vs. 1.5 mmHg in the liraglutide 3.0 mg vs. placebo groups. Diastolic blood pressured was reduced by 2.6 mm Hg vs. 1.9 mm Hg. The most significant change in lipid profile was in the triglycerides that were reduced by 13.0 mg/dl in the liraglutide 3.0 mg group vs. 5.5 mg/dl in the placebo group. Participants assigned to liraglutide 3.0 had a lower frequency of prediabetes and were less likely to develop T2D than those assigned to placebo (28), an outcome that persisted in a 3-year extension analysis (75). For participants with obesity and moderate/severe obstructive sleep apnea, liraglutide 3.0 mg treatment resulted in significantly greater reductions than placebo in apnea-hypopnea index, body weight, SBP, and HbA1c levels (76).

In the SCALE Diabetes study, HbA1c levels were 0.93% lower in the liraglutide 3.0 vs. placebo treated group, and similar significant benefits on triglyceride (lower) and HDL cholesterol (higher) as in the SCALE Obesity study were reported (73).

Although liraglutide 3.0 mg was not evaluated in a cardiovascular outcomes trial (CVOT), the lower dose liraglutide 1.8 mg (Victoza), approved for T2D, was assessed in the LEADER trial (77). The primary outcome was a composite of major adverse cardiovascular events (MACE) including CVD death, nonfatal myocardial infarction (MI), and nonfatal stroke. Adults with T2D and baseline average BMI 32.5 kg/m2 were randomized to liraglutide 1.8 mg vs. placebo. Approximately 81% of participants had established CVD. After a median of 3.8 years, individuals on liraglutide 1.8 mg demonstrated a 13% risk reduction in 3-point MACE compared to placebo. Analysis of additional outcomes showed a 22% reduction in CVD death and a 15% reduction in all-cause deaths. This risk reduction was driven primarily by a reduction in death from CV causes (p=0.01 for superiority) and all-cause mortality was reduced by 15%. Statistical significance was not achieved with individual endpoints of nonfatal MI or nonfatal stroke. Liraglutide 1.8 mg is now FDA-approved for secondary CV prevention in adults with T2D (78).

**Safety and Side Effects**

Gastrointestinal symptoms, such as nausea, vomiting and abdominal pain were the most common reason subjects withdrew from the SCALE trials. In a secondary analysis of these trials, treatment with liraglutide 3.0 resulted in dose-independent, reversible increases in amylase/lipase activity (7% for amylase and 31% for lipase) (79). Thirteen subjects (0.4%) in the liraglutide 3.0 group compared to one (0.1%) with placebo developed pancreatitis, but nearly half of these had evidence for gallstones as well (79). Even though liraglutide treatment showed improvements in blood pressure and lipids, it was found to increase heart rate by an average of 2 beats/min in SCALE Diabetes (73). Animal studies with liraglutide showing an association with medullary thyroid cancer have led to FDA label warnings. Even though the relevance of this observation to humans has not been determined, a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2) is considered a contraindication for treatment with this medication (80).

Women of child-bearing age should have a pregnancy test prior to starting the medicine and be using contraception while taking it.

**SETMELANOTIDE**

Setmelanotide (trade name Imcivree) is a melanocortin-4-receptor (MC4R) agonist that was FDA-approved in November 2020 for the treatment of monogenic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in individuals ages 6 or older (81). Binding of leptin to its receptor causes intracellular PCSK1 to cleave the POMC peptide into alpha-melanocyte stimulating hormone (ɑMSH), which is the endogenous agonist of MC4R (82). Deficiencies in this pathway manifest clinically as hyperphagia, impaired pubertal development, obesity, and insulin resistance with individuals who are homozygous or compound heterozygous for deleterious mutations in POMC also presenting with adrenal insufficiency and hypopigmentation. Setmelanotide is administered as a once daily subcutaneous injection starting at 2 mg daily in patients age 12 or older and 1 mg daily in patients age 6 to less than 12 years. Dose may be titrated up to a maximum of 3 mg daily depending on tolerance and efficacy.

**Efficacy**

A single-arm, open-label, multicenter phase 3 trial of 21 participants aged 6 years and older evaluated the efficacy of setmelanotide for weight loss in patients with POMC deficiency (homozygous or compound heterozygous variants in POMC or PCSK1) or LEPR deficiency (83). After 12 weeks of treatment, those who lost at least 5 kg (or 5% if baseline weight was <100 kg) were then continued into an 8-week placebo-controlled withdrawal phase consisting of 4 weeks each of blinded setmelanotide or placebo treatment followed by an additional 32 weeks of open-label treatment. After approximately 1-year, mean weight loss was 25.6% among individuals with POMC deficiency and 12.5% among those with LEPR deficiency. Eight (80%) participants with POMC deficiency and 5 (45%) participants with LEPR deficiency achieved ≥ 10% weight loss.

**Effect on Metabolic Profile**

Individuals with POMC deficiency experienced an absolute reduction in HbA1c of -0.3%, and those with LEPR deficiency saw a reduction of -0.2%, neither of which were statistically significant. Lipid profiles improved among all participants: HDL increased by 45.0% and 19.6%, LDL decreased by -7.6% and -10.0%, and triglycerides decreased by -36.6% and -7.0% in POMC and LEPR deficiency groups, respectively.

**Safety and Side Effects**

The most common adverse events were injection site reactions, hyperpigmentation, and nausea. No clinically significant changes in heart rate or blood pressure were observed. Spontaneous penile erections in males have occurred (81). Though the manufacturer warns of suicidal ideation and depression, the phase 3 trial reported one case of suicidal ideation not present at baseline and no treatment-related worsening in depression (83).

**SEMAGLUTIDE 2.4**

Semaglutide 2.4mg (trade name Wegovy) is FDA-approved for two indications:

1. To reduce the risk of MACE in adults with established CVD and either obesity or overweight.
2. To reduce excess body weight and maintain weight reduction long term in (1) adults with obesity or overweight plus at least one weight-related comorbidity and (2) pediatric patients aged 12 years and older with obesity.

Semaglutide is a long-acting GLP-1 analogue administered via weekly subcutaneous injection at doses of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg (84). It promotes weight loss through multiple mechanisms including slowing gastric emptying, thereby reducing hunger and energy intake, in addition to direct anorexigenic effects on the brain leading to increased satiety (85).

**Efficacy**

Semaglutide Treatment Effect in People with obesity (STEP) trials 1-4 evaluated the effect of semaglutide 2.4mg once weekly on weight loss in patients with overweight or obesity, with and without T2D (86-89). STEP 1-4 are 68-week, phase 3, double-blind, randomized, multicenter trials. STEP 1 (n=1961) was conducted in adult patients with obesity/overweight without T2D and demonstrated an average placebo-subtracted weight loss of 12.4% with 86.4% achieving ≥ 5% weight loss compared to 31.5% with placebo. STEP 2 (n=1210) was conducted in adults with obesity or overweight and T2D and found an average placebo-subtracted weight loss of 6.2%, with 68.8% achieving ≥ 5% weight loss compared to 28.5% with placebo. STEP 3 (n=611) treated adults with obesity or overweight with semaglutide 2.4 mg as an adjunct to intensive behavioral therapy (IBT) and found an average placebo-subtracted weight loss of 10.3%, with 86.6% achieving ≥ 5% weight loss compared to 47.6% with placebo plus IBT. STEP 4 (n=902) examined the efficacy of semaglutide 2.4mg weekly in maintaining weight loss achieved after a 20-week run-in period (16 weeks of dose escalation; 4 weeks of maintenance dose). Among the 803 patients who completed the run-in period with a mean weight loss of 10.6%, those continued on semaglutide from week 20 to 68 achieved further average weight loss of 7.9% versus an average weight gain of 6.8% in those randomized to placebo after the run-in period. The durability of semaglutide 2.4 mg for weight loss was established by STEP 5 (n=304), which reported mean weight change of -15.2% in the semaglutide group vs -2.6% in the placebo group over a period of 104 weeks (90). Conducted in Japan and South Korea, STEP 6 diversified the eligible population by enrolling adults with BMI ≥ 27 with at least two weight-related comorbidities or BMI ≥35 with at least one weight-related comorbidity. At 68 weeks, mean weight change was -13.2% with semaglutide 2.4 mg, -9.6% with semaglutide 1.7 mg, and -2.1% with placebo (91). STEP TEENS garnered semaglutide’s FDA-approval for treatment of obesity in pediatric and adolescents aged 12 years and older, demonstrating 16.1% weight loss with semaglutide vs 0.6% weight gain with placebo over 68 weeks (92).

Evidence for efficacy compared to similar agents is limited. In a 52-week multicenter phase 2 RCT conducted in adults with obesity and without T2D, semaglutide 0.2-0.4 mg/d demonstrated weight loss superiority compared to liraglutide 3.0 mg/d or placebo (93). The phase 3 RCT, STEP 8, randomized adults with obesity without T2D to liraglutide 3.0 mg/d or semaglutide 2.4 mg/wk or respective placebos (94). After 68 weeks, mean body weight change from baseline was significantly greater with semaglutide: -15.8% with semaglutide vs -6.4% with liraglutide.

In March 2024, semaglutide 2.4 mg received FDA-approval for the treatment of CVD in adults with preexisting CVD and obesity or overweight. In the SELECT trial, adults age 45 years or greater with BMI ≥ 27 and preexisting cardiovascular disease were randomized to semaglutide 2.4 mg vs placebo to investigate the primary endpoint of 3-point MACE: death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (95). After a mean follow-up duration of 39.8± 9.4 months, the primary endpoint occurred in 6.5% of participants in the semaglutide group vs 8.0% in the placebo group, resulting in a relative risk reduction of 20%. The SELECT trial builds upon an established body of evidence (e.g., SUSTAIN-6) demonstrating the CV safety and benefits of semaglutide and is groundbreaking as the first CVOT to demonstrate secondary cardiovascular prevention with an anti-obesity medication in a population without T2D.

**Effect on Metabolic Profile**

Secondary endpoints in the STEP 1 trial included weight circumference, blood pressure, lipids, c-reactive protein, HbA1c, and physical functioning scores (SF-36, IWQOL-Lite-CT), all of which showed significantly greater improvement than placebo (133). SBP was reduced by -6.16 mmHg vs. -1.06 mmHg in the semaglutide 2.4 mg vs. placebo groups. Diastolic blood pressure decreased by -2.83 mmHg vs. -0.42 in the semaglutide 2.4 mg vs. placebo groups. HbA1c decreased by -0.52% vs. -0.17% in semaglutide 2.4 vs. placebo groups, with 84.1% of participants achieving normoglycemia at 68 weeks on semaglutide 2.4 vs. 47.8% of patients on placebo. In the STEP 2 trial, conducted in adults with obesity and T2D, HbA1c levels at 68 weeks were reduced by -1.6% in the semaglutide 2.4 vs. -1.5% in the semaglutide 1.0 vs. -0.4% in the placebo group, and 78.5%, 72.3%, and 26.5% achieved an HbA1c<7.0 (89). There were also significant improvements over placebo in SBP, triglycerides, C-reactive protein and physical functioning scores. A secondary analysis of the SELECT trial demonstrated semaglutide’s potential for the primary prevention of T2D and for the regression of T2D: only 1.5% vs 6.9% with placebo had biochemical diabetes by week 156, establishing a number needed to treat (NNT) of 18.5 to prevent one case of diabetes (96). Furthermore, 69.5% vs 35.8% achieved diabetes regression, defined biochemically as A1c <5.7 (i.e., normoglycemia).

The SELECT trial also examined the pre-specified main composite kidney endpoint of: death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) (97). This endpoint was observed in 1.8% of participants on semaglutide 2.4 mg vs 2.2% of participants on placebo, resulting in a relative risk reduction of 22%. No particular subgroup with respect to age, sex, race, ethnicity, baseline eGFR (<60 or ≥60), baseline UACR (<30, 30 to <300, ≥300), baseline body weight, baseline BMI, baseline A1c, or CVD inclusion criteria were found to have a statistically significant interaction with the treatment effect of semaglutide. The FLOW trial established renal benefit with semaglutide 1.0 mg in adults with T2D and CKD (98): after a median of 3.4 years, semaglutide resulted in a 24% relative risk reduction in the primary outcome defined as a composite of the onset of kidney failure (dialysis, transplantation, or eGFR <15 ), ≥50% reduction in the eGFR from baseline, or death from kidney-related or cardiovascular causes.

A dedicated phase 2 trial for the treatment of non-alcoholic steatohepatitis (NASH) involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3 determined semaglutide 0.1 mg/d, 0.2 mg/d, or 0.4 mg/d was more effective than placebo for achieving NASH resolution with no worsening of fibrosis: 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (99). The mean percent weight loss was 13% in the 0.4-mg group vs 1% in the placebo group.

Additional cardiovascular protection has been proven in heart failure with preserved ejection fraction (HFpEF). Semaglutide 2.4 mg was demonstrated in the STEP HFpEF trial to significantly improve the Kansas City Cardiomyopathy Questionnaire clinical summary score by 16.6 points vs 8.7 points with placebo in adults with HFpEF and obesity (BMI ≥ 30) (100). Mean change in body weight was -13.3% with semaglutide and -2.6% with placebo over 52 weeks. The improvement in HFpEF symptoms may be mediated by weight-independent mechanisms and measurable via reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP)(101).

**Safety and Side Effects**

The most common side effects in phase 3 RCTs of semaglutide 2.4mg were nausea, diarrhea, vomiting and constipation. In the STEP 1 trial, these gastrointestinal side effects occurred more often in those receiving semaglutide vs. placebo (74.2% vs. 47.9%). However, most of these were mild-moderate in severity; serious adverse events occurred in 9.8% of those receiving semaglutide vs. 6.4% of those on placebo. Serious adverse events included serious gastrointestinal disorders (1.4% with semaglutide vs. 0% with placebo), hepatobiliary disorders (1.3% with semaglutide vs. 0.2% with placebo), gallbladder disorders (2.6% with semaglutide vs. 1.2% with placebo), and mild acute pancreatitis (0.2% with semaglutide vs. 0% placebo). Across all RCTs, participants experienced an average increase in heart rate of 1-4 beats per minute (bpm); 26% of individuals on semaglutide vs. 16% of those on placebo had increased heart rates by 20 bpm or more (84). Among patients with T2D, hypoglycemia occurred in 6.2% of patients treated with semaglutide vs. 2.5% of patients on placebo (89). Psychiatric side effects did not emerge as a treatment-related adverse event, and a real-world cohort study of over 200,000 patients found no evidence for increased risk of suicidal ideation (102).

Like liraglutide, semaglutide is contraindicated in the setting of a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. In rodents, semaglutide was found to cause thyroid C-cell tumors, but no human cases have been linked to semaglutide use. A narrative review of RCT and real-world data found no compelling link between semaglutide and thyroid cancer (103), and a systematic review and meta-analysis further concluded there was no increased risk of any cancer with semaglutide (104). Women of child-bearing age should have a pregnancy test prior to starting the medicine and be using contraception while taking it. Semaglutide 2.4mg should be discontinued at least 2 months prior to conception per manufacturer’s recommendation (84).

**TIRZEPATIDE**

Tirzepatide (trade name Zepbound) is approved for the treatment of obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Tirzepatide is a first-in-class dual agonist at GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors. It is administered via once weekly subcutaneous injection at doses of 2.5, 5, 7.5, 10, 12.5, and 15 mg. Tirzepatide is biased towards GIP activity, with less GLP1 agonism compared to endogenous GLP1. With respect to potential mechanisms for cardiometabolic protection and weight loss, the actions of GIP may include (105):

1. Reduction in caloric intake.
2. Increase in glucose and triglyceride uptake at adipose tissue.
3. Increase in insulin sensitivity.

Additional mechanisms involving both GIP and GLP1 pathways may also contribute to weight loss (106), though significant nuance exists in understanding their actions as investigated in mouse vs human studies (107).

**Efficacy**

Tirzepatide has been investigated for the treatment of obesity in four phase 3 RCTs thus far: SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4.

SURMOUNT-1 enrolled 2539 participants with BMI ≥ 30 or ≥ 27 with at least one weight-related comorbidity who were randomized to 5, 10, or 15 mg of tirzepatide or placebo for 72 weeks (108). Baseline weight was 104.8 kg and baseline BMI was 38.0. The mean weight change was -15.0%, -19.5%, -20.9%, and -3.1% with tirzepatide 5 mg, 10 mg, 15 mg, and placebo, respectively. Categorical weight loss outcomes for tirzepatide 5 mg, 10 mg, 15 mg, and placebo were: 85%, 89%, 91%, and 35%, respectively.

In SURMOUNT-2, adults with BMI ≥ 27 and A1c 7-10% on stable anti-diabetic therapy, either diet and exercise alone or oral antihyperglycemic medication for at least 3 months were randomized to tirzepatide 10 mg, 15 mg, or placebo for 72 weeks (109). Baseline weight was 100.7 kg, BMI 36.1, and A1c 8.02%. On average, duration of diabetes was 8.5 years. Change in weight was -12.8%, -14.7%, and -3.2% with tirzepatide 10 mg, 15 mg, and placebo, respectively. Participants who achieved ≥5% weight loss were 79%, 83%, and 32%, respectively. A1c was equally reduced by 2.1% with both tirzepatide 10 mg and 15 mg vs 0.5% with placebo. A post hoc analysis showed that the proportion of participants who increased anti-diabetic therapy intensity decreased in the tirzepatide arms and increased in the placebo arm.

SURMOUNT-3 investigated the effect of tirzepatide (10 mg or 15 mg) vs placebo after ≥5% weight loss with ILI in adults with BMI ≥ 30 or ≥ 27 and at least one weight-related comorbidity. At baseline, weight was 110.1 kg and BMI was 38.7. After 72 weeks, participants on tirzepatide lost 18.4% of their baseline weight while those on placebo gained 2.5%. Significant more people on tirzepatide than placebo achieved ≥5% weight loss: 87.5% vs 16.5%. The numerically lower average weight loss achieved in SURMOUNT-3 compared to that in SURMOUNT-1 has called into question the role of lifestyle management in the era of highly effective AOMs, but several potential areas of benefit have been identified, outside of weight: body composition and preservation of lean muscle mass, micronutrient adequacy, and cementation of behavior strategies associated with long-term weight loss maintenance (110).

SURMOUNT-4 examined the efficacy of tirzepatide (10 or 15 mg) vs placebo for weight loss maintenance in adults who completed a 36-week lead-in weight loss period. At the end of 36 weeks, average weight loss was 20.9% with tirzepatide vs --- with placebo. From week 36 to week 88, participants lost an addition 5.5% with tirzepatide and gained 14.0% with placebo. Overall, tirzepatide resulted in weight loss maintenance, defined as ≥ 80% of weight lost, for 89.5% of participants compared to only 16.6% of those on placebo. The total mean weight change from week 0 to 88 was -25.3% vs -9.9% in tirzepatide vs placebo arms.

The SURMOUNT trials were notable for a few unique characteristics:

* New in-class mechanism of action incorporating GIP agonism.
* More balanced male-to-female recruitment approximating 50%, compared to prior obesity clinical trials.
* A new threshold achieved for average weight loss, greater than 20%, a milestone approaching and surpassing that of some bariatric surgeries.

Pending SURMOUNT trials include SURMOUNT-5, a head-to-head trial of tirzepatide vs semaglutide for obesity, and SURMOUNT-MMO, tirzepatide’s CVOT.

**Effect on Metabolic Profile**

The benefits of tirzepatide on cardiometabolic risk factors was consistent across all trials. Participants on tirzepatide experienced significantly greater improvements in SBP, DBP, fasting insulin, fasting glucose, A1c, LDL cholesterol, HDL cholesterol, and triglycerides compared to placebo. In SURMOUNT-1, -2, and -3, SBP decreased by 5 to 7 mmHg with tirzepatide vs no change or increase in placebo groups. In SURMOUNT-4, during the weight loss maintenance phase, SBP increased by 2.1 mmHg with tirzepatide vs 8.4 mmHg with placebo. Insulin sensitivity improved among tirzepatide groups, with fasting insulin reduced by about 40% in SURMOUNT-1, -3, and -4. Among participants with obesity and T2D in SURMOUNT-2, A1c was reduced by about 2% with tirzepatide 10 or 15 mg vs 0.5% with placebo. The most dramatic improvements in lipid profiles remained the reduction of triglycerides of about 25% in SURMOUNT-1, -2, and -3, and up to 33% in SURMOUNT-4.

Tirzepatide has recently been investigated in a phase 3 trial specific for benefits in obstructive sleep apnea (OSA). The SURMOUNT-OSA trial (n=469) assessed the safety and efficacy of tirzepatide 10 or 15mg weekly on adults with moderate-to-severe OSA and a BMI ≥30 (111). At 52 weeks, the trial showed a significant reduction in the apnea-hypopnea index (AHI) both in participants who were and were not receiving positive airway pressure (PAP) at baseline. In participants not receiving PAP therapy, those on tirzepatide had a reduction in AHI by -25.3 events/hr vs, -5.3 events/hr in placebo and a placebo subtracted weight loss of -16.1%. Similarly, in participants receiving PAP therapy at baseline, those on tirzepatide had a reduction in AHI by -29.3 event/hr vs. -5.5 events/hr in placebo and placebo subtracted weight loss of 17.3%.

In a phase 2 study (SYNERGY-NASH) of participants with biopsy-confirmed metabolic-associated steatohepatitis (MASH) and stage F2 or F3 fibrosis, a significantly greater proportion of participants achieved resolution of MASH without worsening of fibrosis in tirzepatide groups compared to placebo after 52 weeks of treatment {Loomba 2024}: 44% (5 mg), 56% (10 mg), 62% (15 mg) vs 10% (placebo).

**Safety and Side Effects**

Across all four SURMOUNT obesity trials, the most common adverse events were gastrointestinal: nausea, vomiting, diarrhea, constipation. Treatment discontinuation rates due to adverse events were generally low (2-8%). No imbalances were noted for incidence of pancreatitis between tirzepatide groups and placebo. No cases of medullary thyroid carcinoma or pancreatic cancer occurred. In general, the incidence of gallbladder disease was numerically greater in tirzepatide groups compared to placebo though the overall incidences were low (<1%).

While all AOMs are contraindicated in pregnancy, tirzepatide has been observed to affect absorption of estradiol-containing oral contraceptives and potentially reduce their efficacy as birth control, specifically during dose escalation phases of tirzepatide. For this reason, individuals of childbearing potential should be counseled to use a second form of birth control during dose escalation. The purported mechanism for this interference is a reduction in gastrointestinal motility and absorption, which may occur with other incretin therapies (i.e., semaglutide, liraglutide), but such interactions have not been reported.

**GELESIS 100**

Gelesis100 (Plenity) is the first anti-obesity agent that is FDA-approved for adults with overweight (BMI 25-40 kg/m2) irrespective of comorbidities. Gelesis100 is a hydrogel matrix composed of modified cellulose cross-linked with citric acid. Its mechanism of action is to absorb water to occupy about one-fourth of the average stomach volume, promoting fullness. Because it achieves its primary intended purpose through a mechanical mode of action, it is considered a device rather than a drug and has no systemic effects. One dose is three oral capsules (2.25 g/dose) that is ingested with 500 ml of water 20-30 min prior to lunch and dinner.

**Efficacy**

The efficacy of Gelesis100 was evaluated in the Gelesis Loss of Weight (GLOW) randomized double-blind placebo-control trial (112). Adults with overweight or obesity with or without comorbidities were randomized to Gelesis100 (n=223) or placebo (n=213) for 6 months, and completers who had lost ≥ 3% of baseline weight after 24 weeks were offered to continue in the 24-week open-label single cross-over extension trial GLOW-EX(112). At 6 months, weight loss was 6.4% vs. 4.4% (p=0.0007) in the Gelesis100 vs. placebo groups, respectively, and 58.6% vs. 42.2% of individuals lost ≥ 5% of baseline weight (p=0.0008). Gelesis100 was not significantly more effective in individuals with prediabetes or drug-naïve T2D with respect to mean percent change in body weight, which had been a notable observation in the pilot study First Loss of Weight (FLOW) (112). However, weight loss of ≥ 10% in this subgroup was achieved by 44% vs. 14% of those on Gelesis100 vs. placebo, respectively. In GLOW-EX (n=39), participants in the Gelesis100 group had achieved at mean of 7.1% weight loss at end of the GLOW trial, and continuation of Gelesis100 resulted in a mean weight loss of 7.6% at 48 weeks, demonstrating weight loss maintenance.

**Effect on Metabolic Profile**

Overall, there were no significant differences between Gelesis100 or placebo in cardiovascular risk factors of LDL-C, HDL-C, triglycerides, systolic BP, diastolic BP, or HOMA-IR. In a subgroup of individuals with elevated LDL-C, blood pressure, or HOMA-IR, there was a greater reduction in LDL-C, resolution of hypertension, and reduction in HOMA-IR in those treated with Gelesis100.

**Safety and Side Effects**

Side effects due to Gelesis100 are commonly gastrointestinal, including abdominal distension, infrequent bowel movements, or dyspepsia. There were no significant differences between groups with regards to serum vitamin levels. Gelesis100 is contraindicated in pregnancy or individuals with allergies to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium oxide (45). It should be avoided in patients with esophageal anatomic anomalies, suspected strictures, or post-operative complications that affect gastrointestinal transit and motility. The manufacturer recommends caution in patients with active gastrointestinal reflux diseases. The impact of Gelesis100 on the absorption of other medications was investigated only with metformin. Concurrent administration of Gelesis100 with metformin in the fasting state reduced the median area-under-the-curve (AUC) for metformin but had no effect on metformin AUC when administered during a meal. It is recommended that Gelesis100 be considered “food” when counseling patients on administration of other medications that require ingestion “on an empty stomach” vs. “with food.”

**NON-FDA APPROVED (OFF-LABEL) MEDICATIONS THAT CAUSE WEIGHT LOSS**

Several medications prescribed for conditions other than obesity have been found to be effective weight loss drugs in patients with obesity. If used for weight loss, the prescribed use of these medications would be off-label.

**Bupropion**

Bupropion (trade name Wellbutrin or Zyban) is used for depression and smoking cessation and can cause weight loss as a side effect. While the mean weight loss seen with bupropion is small, it is a preferred alternative to most antidepressants, which commonly cause weight gain.

A 48-week randomized placebo-controlled trial randomized individuals with obesity to placebo, 300 mg, or 400 mg of bupropion sustained release (SR). Percentage losses of initial body weight for subjects completing 24 weeks were 5.0%, 7.2%, and 10.1% for placebo, bupropion SR 300, and 400 mg/d, respectively (113). In subjects with obesity and depressive symptoms, bupropion SR was more effective than placebo in achieving weight-loss when combined with a 500 kcal deficit diet (4.6% vs.1.8% loss of baseline body weight, P<0.001) (114). Bupropion is contraindicated in patients with seizures, current or prior diagnosis of bulimia or anorexia nervosa, and concurrent use with MAOs (115). Caution should be used in patients with hypertension, mania/hypomania, psychosis, and angle-closure glaucoma.

**Metformin**

Metformin (trade name Glucophage) is an antihyperglycemic agent that acts by suppressing gluconeogenesis and increasing peripheral insulin sensitivity (116). Potential weight loss mechanisms include:

1. Activation of AMP-activated protein kinase (AMPK) to mimic an “energy deficient” state (117,118).
2. Increasing anorexigenic hormones GLP-1 (119), growth/differentiation factor-15 (GDF-15) (120), neuropeptide Y (NPY), and agouti-related protein (AgRP) (121).
3. Increasing leptin sensitivity (122).

In the landmark Diabetes Prevention Program (DPP), 3234 participants without T2D but with fasting and post-prandial hyperglycemia were randomized to intensive lifestyle intervention (ILI), metformin, or placebo (14). ILI consisted of a 7% weight loss goal, 150 minutes per week of physical activity, and a low-fat diet. The mean age was 51 years and mean BMI was 34.0 kg/m2. The metformin group was not offered ILI and was assigned to metformin 850 mg twice a day. After an average follow-up of 2.8 years, patients in the metformin group achieved greater weight loss than placebo but less than the ILI group. The average weight loss was 0.1 kg, 2.1 kg, and 5.6 kg in the placebo, metformin, and ILI groups, respectively (*P*<0.001, cross-group comparison) (14). The extended observational trial DPP Observation Study showed that the group on metformin maintained 3% weight reduction compared to placebo for 6-15 years after DPP ended (123). Short-term studies and meta-analyses in individuals with obesity and without prediabetes/diabetes consistently demonstrate ~2% weight loss beyond placebo, with a greater response in those with more insulin resistance (124). Metformin is therefore considered a first line drug in treating patients with T2D and obesity. The most common side effects of metformin are nausea, flatulence, diarrhea, and bloating (125). The most serious side effect is lactic acidosis, but this is rare (<1/100,000) (126). Monitoring for vitamin B12 deficiency is recommend as long-term use of metformin has been associated with low vitamin B12 levels and neuropathy (127).

**Pramlintide**

Pramlintide acetate (trade name Symlin) is an injectable agent that is FDA-approved for the treatment of type 1 and T2D. Pramlintide mimics the action of the pancreatic hormone amylin, which along with insulin regulates postprandial glucose control. Its effect on weight loss is thought to be mediated through central (brain) receptors (128) that improve appetite control (129). In a pooled, post-hoc analysis of overweight and obese insulin-treated patients with T2D, pramlintide-treated patients (receiving 120 ug twice daily) had a body weight reduction of -1.8 kg (P<0.0001) compared with placebo-treated patients (130). In this study, pramlintide-treated patients experienced a 3-fold increase in successfully achieving a total body weight loss of ≥ 5%, when compared to those who received placebo. Subsequently, randomized trials combining pramlintide or placebo with a lifestyle intervention were undertaken in obese participants without diabetes. Treatment with pramlintide (up to 240 ug three time daily) for 16 weeks resulted in a placebo-corrected reduction in body weight of 3.7% (P<0.001) and 31% of pramlintide-treated subjects achieved ≥5% weight loss vs. 2% with placebo (P<0.001) (131). In another study with one year follow-up, placebo-corrected weight loss in those taking 120 g three time daily and 360 ug twice daily averaged 5.6% and 6.8% (132). Nausea is the most common adverse event with pramlintide treatment in these studies.

**Sodium-Glucose Transporter-2 Inhibitors**

Sodium-glucose transport-2 (SLGT2) inhibitors are a class of medications used for the treatment of T2D. Inhibition of SGLT2 in the kidney lowers the renal threshold for glucose reabsorption, resulting in glucosuria and improved plasma glucose levels. As of 2024, there are five SLGT2 inhibitors approved in the U.S.: canagliflozin (Invokana), dapagliflozin (Farxiga), ertugliflozin (Steglatro), empagliflozin (Jardiance), and bexagliflozin (Brenzavvy). Pooled analyses of four phase 3 trials in adults with T2D showed about 2-3% placebo-subtracted weight loss with canagliflozin 100-300 mg/d at 26 weeks (133). Dapagliflozin on a background of metformin was found to result in a placebo-subtracted weight loss of 2.42kg at 102 weeks in adults with T2D and obesity (134). In the landmark EMPA-REG CVOT, average placebo-subtracted weight loss of about 2 kg was maintained out to 220 weeks with empagliflozin 25 mg (135). The fourth SGLT2 inhibitor, ertugliflozin, also resulted in about 2kg weight loss over placebo in adults with T2D treated for 26 weeks (136). A meta-analysis of EMPA-REG, CANVAS (137,138), and DECLARE-TIMI 58 (139) found that SGLT2 inhibitors were associated with a 24% reduction in hospitalization for heart failure and CVD death in individuals with T2D and established CVD (140). This same meta-analysis concluded that SGLT2 inhibitors were also associated with nearly a 50% reduction in the composite outcome of end-stage renal disease, renal worsening, or renal failure in individuals with T2D and CVD or CVD risk factors. The reno-protective effect may be independent of baseline A1c given attenuated eGFR declines observed in CREDENCE and DAPA-HF trials with little change in A1c (141,142), suggesting a role of SGLT2 inhibitors in individuals with nephropathy without T2D. Dapagliflozin was recently approved by the FDA for the treatment of heart failure in individuals with or without T2D based on the results of the DAPA-HF trial (142). EMPEROR-Preserved and EMPEROR-Reduced established similar benefits of empagliflozin in heart failure irrespective of ejection fraction (143).

DAPA-CKD and EMPA-KIDNEY evaluated the effect of SGLT2 inhibitors in the broader CKD population (144,145). In DAPA-CKD, adults with eGFR 25-75 and urinary albumin-to-creatinine ratio (UACR) of 200-5000 were randomized to dapagliflozin 10 mg or placebo (146). The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes. After a median of 2.4 years, the primary outcome occurred in 9.2% vs 14.5% in the dapagliflozin vs placebo groups, respectively, representing a 39% relative risk reduction. In EMPA-KIDNEY, adults with eGFR 20-45 or eGFR 45-90 with UACR ≥200 were randomized to empagliflozin 10 mg or placebo (147). The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to <10 ml per minute per 1.73 m2, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes. After a median of 2.0 years, the primary outcome occurred in 13.1% vs 16.9% in the empagliflozin and placebo groups, respectively, representing a 28% relative risk reduction.

Data for bexagliflozin is comparatively scarce to other members of its class. In a phase 3 RCT of adults with T2D and stage 3a/3b CKD, bexagliflozin resulted in A1c reduction of 0.59-0.65% vs 0.16-0.34% with placebo, depending on eGFR (148).

Due to the mechanism of action, all SGLT2 inhibitors may cause urinary tract infections, genital mycotic infections, and dehydration. They are contraindicated in end-stage renal disease and dialysis (149-152).

**Topiramate**

Topiramate (trade name Topamax) is an antiepileptic agent that has been found to reduce body weight in patients with a variety of disorders including epilepsy, bipolar disorder, and binge eating disorder (153). Randomized controlled trials have shown that topiramate is both tolerable and effective in promoting weight loss (61). In addition to use for epilepsy, topiramate has received FDA approval for the prevention of migraine headaches. Topiramate can cause paresthesias and cognitive side effects, such as word-finding difficulty and memory loss. Caution should be taken if used in patients predisposed to renal stones, acute angle glaucoma, or metabolic acidosis (154).

**Zonisamide**

Zonisamide (trade name Zonegran) is another antiepileptic medication that has also been found to reduce body weight in patients. Short (16 weeks) and longer (one year) randomized-controlled studies in patients with obesity have shown that 400 mg of zonisamide daily is effective in promoting modest weight loss (~5 kg placebo-subtracted weight) (155,156). The most commonly reported side effects compared to placebo were gastrointestinal (nausea/vomiting), nervous system (headaches), and cognitive (anxiety, impaired memory, language problems) (156). Zonisamide should not be given to patients hypersensitive to sulfonamides (157).

**Metreleptin**

Metreleptin (trade name Myalept) is a leptin analog approved to treat the complications of leptin deficiency in individuals with congenital or acquired generalized lipodystrophy (158). It has been used off-label for the treatment of obesity and other endocrine complications in people with congenital leptin deficiency and hypothalamic amenorrhea (159). Metreleptin is administered as a once daily subcutaneous injection with dosages ranging from 0.06 mg/kg/d to 10 mg/d, depending on body weight and sex. Additional precautions should be implemented if it is being considered for individuals with T-cell lymphoma or autoimmune disorders. During therapy, patients should be tested for neutralizing anti-metreleptin antibodies if they develop severe infections or loss of efficacy. Common side effects include headache, hypoglycemia, decreased weight, and abdominal pain.

**MEDICATION-INDUCED OBESITY**

The role of medications as a factor that can induce weight gain is often overlooked. Several commonly prescribed medications as well as over-the-counter medications are associated with significant weight gain. This includes medications used to treat T2D, hypertension, depression, schizophrenia, and insomnia (160-162). When evaluating a patient with obesity for the first time, the clinician should perform a thorough review of all current prescription and over-the-counter medications to investigate for potential weight-gaining medications. Whenever possible, the clinician should consider alternatives to medications known to cause weight gain (163), or should consider measures that would ameliorate the weight-gaining effect of the prescribed drug.

**FUTURE DIRECTIONS FOR WEIGHT-LOSS MEDICATIONS**

Medical providers, policy makers, and pharmaceutical industries have increasingly recognized the need for safe and effective pharmacotherapy for patients with overweight or obesity. With the advent of highly effective nutrient-stimulated hormone therapies (NuSH) (e.g., semaglutide, tirzepatide) achieving weight loss thresholds of ≥15% necessary to resolve comorbid diseases, a new generation of AOMs have arrived to significantly shift the trajectory of the obesity epidemic. Several AOMs are currently in various stages of development and are increasingly focused on multi-target strategies. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors that has been shown to have a 100% response rate for clinically significant weight loss and an average weight loss of 24% in a phase 2 trial (164). Semaglutide 2.4 mg in combination with cagrilintide, an amylin analog, has been shown to cause 15% weight loss in a phase 2 trial (165). Interest is also burgeoning into increasing scalability and accessibility. Small molecule oral AOMs are potential solutions. Orforglipron is a small molecule GLP-1RA that has also demonstrated about 15% weight loss in a phase 2 trial (166). Innovators are also exploring peripheral targets outside of NuSH mechanisms that do not rely on anorexigenic effects to mediate weight loss. Bimagrumab is a first-in-class novel AOM that is a monoclonal antibody against activin type 2 receptors on skeletal myoblasts; its phase 2 trial focused on the unique endpoint of fat mass loss rather than total body weight loss (167). With the advent of highly effective AOMs and newer agents targeted specifically at fat mass loss, pharmacotherapy is likely to become more acceptable by society and the medical community to treat obesity as a disease.

**IMPLICATIONS FOR PRACTICE**

The plethora of on- and off-label AOMs creates the unique challenge for physicians to decide which medication may be most appropriate for the individual patient. Akin to management of other chronic diseases, selection of an AOM should be based on safety and tolerability, comorbidities, and accessibility.

The following principles could serve as a guide the physician in choice of AOM:

* **Safety and tolerability:** Avoid medications for which the patient has contraindications or is at risk of intolerability due to the medications side effect profile. A patient with HTN and lower extremity edema may be better treated with a diuretic rather than amlodipine, which may have the side effect of leg swelling. Analogously, in a patient with obesity and HTN or anxiety, sympathomimetics like phentermine and bupropion/naltrexone should be avoided or used with caution due to potential side effects of these AOMs.
* **Comorbidities:** Target treatment to multiple comorbidities when possible, taking advantage of medications that have dual indications. A patient with HTN and T2D complicated by microalbuminuria would be recommended for an angiotensin converting enzyme inhibitor (ACEi) or aldosterone receptor blocker (ARB) instead of a calcium channel blocker because of the dual benefits of ACEi’s or ARBs. Analogously, in obesity and T2D, semaglutide or tirzepatide would be preferred due to their dual indications and additional cardiovascular benefit in those with preexisting cardiovascular disease. Selection of an AOM may also depend on the degree of weight loss desired and associated health goal. For example, resolution of OSA is likely to require ≥15% weight loss, which is more likely to be achieved with semaglutide or tirzepatide; whereas a patient with prediabetes seeking diabetes prevention can be effectively protected with just 5% weight loss, achievable with most on- and off-label AOMs.

* **Combinations of AOMs:** Combining medications with complementary mechanisms of action is a rational management strategy to target the pathophysiology of obesity and metabolic adaptation. For example, a patient who has lost weight with metformin and reached a weight loss plateau may experience increased hunger due to higher levels of ghrelin, a mechanism that has been reported after diet-induced weight loss; an appetite suppressant such as phentermine or phentermine/topiramate may be helpful to mitigate this compensatory mechanism. While some of these combinations have been investigated (168,169), most AOM permutations have not been tested in RCTs, and the “how” and “when” of AOM combinatorial approaches remains in the realm of clinical judgement and future research. Combinations of off-label AOMs have been associated with significant long-term weight loss and may be a pragmatic approach to increase access to evidence-based obesity care in an era when on-label AOMs are poorly covered by insurance {Weintraub 2023}.

Overall, the approach to obesity management should adopt a comprehensive, multidisciplinary approach to address the root cause (i.e., obesity) as well as its downstream consequences. The decision to pursue obesity pharmacotherapy and the choice of AOM should be made in conjunction with an engaged care team and relevant specialists especially if specific populations are being managed (Table 3).

|  |
| --- |
| **Table 3. Choice of AOM in Special Populations** |
| **Special Population** | **Care Team** | **Specific Considerations** |
| Post-bariatric surgery weight regain | Bariatric surgeon, registered dietitian-nutritionist | Absorption of oral medications may be affected by specific surgeries {Angeles 2019}Moderate evidence exists to treat post-bariatric surgery weight gain with AOMs {Barenbaum 2022} |
| Depression, anxiety, severe mental illness | Psychiatrist, psychologist | Some psychotropic medications are associated with weight gain {Apovian 2014} |
| Eating disorder (e.g., atypical anorexia, avoidant/restrictive food intake disorder, bulimia nervosa, binge eating) | Psychiatrist, psychologist | Screen for disordered eating at initial visit {Freshwater 2022} |
| Individuals of child-bearing potential | Obstetrician-gynecologist | All AOMs are contraindicated in pregnancy, and some are suspected to affect contraception efficacy |
| Elderly | Geriatrician, exercise physiologist | Excess weight loss without sufficient physical activity may predispose individual to sarcopenic obesity and frailty {Prado 2024} |

**CONCLUSION**

The obesity pandemic continues to grow at an alarming rate. Because lifestyle modifications have been limited in their success in weight loss maintenance, pharmacotherapy plays an important role in achieving clinically significant weight loss and preventing the development or exacerbation of comorbid conditions. As society and the scientific community furthers our understanding of obesity, obesity management will evolve to match the standard of care of other chronic conditions, recognizing polypharmacotherapy as a vital component of comprehensive care.

**REFERENCES**

1. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. NCHS Data Brief. 2015(219):1-8.

2. World Health Organization (WHO). Overweight and Obesity. Vol 20202020.

3. Centers for Disease Control and Prevention (CDC). Overweight & Obesity: Adult Obesity Facts. Vol 20212020.

4. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker SL. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450.

5. Organisation for Economic Co-operation and Development (OECD). Obesity Update. 2017.

6. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1923-1994.

7. Jayawardana R, Ranasinghe P, Sheriff MH, Matthews DR, Katulanda P. Waist to height ratio: a better anthropometric marker of diabetes and cardio-metabolic risks in South Asian adults. Diabetes Res Clin Pract. 2013;99(3):292-299.

8. Bray GA. Medical consequences of obesity. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2583-2589.

9. Stein CJ, Colditz GA. The epidemic of obesity. The Journal of clinical endocrinology and metabolism. 2004;89(6):2522-2525.

10. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition. 2004;92(3):347-355.

11. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European journal of endocrinology / European Federation of Endocrine Societies. 2003;149(4):331-335.

12. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med. 2003;41(9):1120-1130.

13. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. British Medical Journal. 2001;322(7288):716-720.

14. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research G. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

15. Foster G. The behavioral approach to treating obesity. Am Heart J. 2006;151(3):625-627.

16. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 SUPPL. 1):102-138.

17. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016;22 Suppl 3:1-203.

18. National Institute of Health (NIH). The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Heart Lung and Blood Institute Guidelines. 2000:1-94.

19. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD, Endocrine S. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2015;100(2):342-362.

20. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. The Journal of clinical investigation. 2003;111(5):565-570.

21. Lowe MR. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res. 2003;11 Suppl:44S-59S.

22. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.

23. Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, Brychta R, Chen KY, Skarulis MC, Walter M, Walter PJ, Hall KD. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring, Md). 2016;24(8):1612-1619.

24. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.

25. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, Group C-IS. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md). 2013;21(5):935-943.

26. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.

27. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring, Md). 2012;20(2):330-342.

28. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, Le Roux CW, Ortiz RV, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Prediabetes and Obesity). New England Journal of Medicine. 2015;373(1):11-22.

29. Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring, Md). 2020;28(3):529-536.

30. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring, Md). 2011;19(1):110-120.

31. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.

32. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Journal of the American Medical Association. 2016;315(22):2424-2434.

33. Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. Obesity (Silver Spring, Md). 2019;27(2):288-294.

34. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380-385.

35. Bray GA, Purnell JQ. An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2024, MDText.com, Inc.; 2000.

36. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, Investigators S. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.

37. Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000-1002.

38. Wright SM, Aronne LJ. Obesity in 2010: the future of obesity medicine: where do we go from here? Nat Rev Endocrinol. 2011;7(2):69-70.

39. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, Investigators C-TSC. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018;392(10161):2269-2279.

40. Kumar RB, Ryan DH. Lorcaserin Departs, Leaving More Questions than Answers. Obesity (Silver Spring, Md). 2020;28(7):1167.

41. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults (EQUATE). Obesity (Silver Spring, Md). 2013;21(11):2163-2171.

42. Cercato C, Roizenblatt VA, Leança CC, Segal A, Lopes Filho AP, Mancini MC, Halpern A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond). 2009;33(8):857-865.

43. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160-167.

44. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E, Group C-IS. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.

45. Plenity (Gelesis100) [package insert]. Boston, MA: Gelesis, Inc.; 2019.

46. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy with phentermine in obesity. Br Med J. 1968;1(5588):352-354.

47. Adipex-p (phentermine) [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2012.

48. Xenical (orlistat) [package insert]. San Francisco, CA: Genentech USA, Inc.; 1999.

49. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82-85.

50. Carrière F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G16-28.

51. Williams G. Orlistat over the counter. British Medical Journal. 2007;335(7631):1163-1164.

52. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8(1):49-61.

53. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172.

54. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Journal of the American Medical Association. 1999;281(3):235-242.

55. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-1294.

56. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033-1041.

57. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248(3):245-254.

58. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001;25(7):1095-1099.

59. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006;29(1):49-60.

60. Hirsch J, Mackintosh RM, Aronne LJ. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res. 2000;8(3):227-233.

61. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, Group O-S. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2004;28(11):1399-1410.

62. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95(3):189-199.

63. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. The American journal of clinical nutrition. 2012;95(2):297-308.

64. Qsymia (phentermine and topiramate extended-release) [package insert]. Winchester, KY: VIVUS Inc.; 2012.

65. Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md). 2015;23 Suppl 1:S7-11.

66. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring, Md). 2009;17(1):30-39.

67. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11.

68. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K, Group CO-DS. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-4029.

69. Contrave (naltrexone HCl and bupropion HCl) [package insert]. San Diego, CA: Nalpropion Pharmaceuticals, Inc.; 2014.

70. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S, Investigators N-T. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. The New England journal of medicine. 2020;382(22):2117-2128.

71. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. American journal of physiology Regulatory, integrative and comparative physiology. 2016;310(10):R885-895.

72. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International journal of obesity. 2014.

73. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA, Valensi P, Levy M, Benabdallah S, Serusclat P, Courreges JP, Gouet D, Clavel S, Cariou B, Tyler K, Hanefeld M, Jordan R, Milek K, Rose L, Sauter J, Steindorf J, Wendish U, Rudofsky G, Erlinger R, Harman-Boehm I, Mosenzon O, Cohen J, Karasik A, Minuchin O, Snyman HH, Komati SM, Naiker P, Lombaard JJ, Podgorski G, Saleh MF, Muñoz M, Parreño LDT, García SD, Esteban BM, Fernández MR, Pérez AMS, Burguera B, Vázquez C, Hemmingsson JU, Eizyk E, Rautio A, Norrby A, Jasinska E, Comlekci A, Gokce C, Gul K, Mansell P, Johnson AB, Millward A, Bilous R, Collier DA, Hitman G, Maxwell T, Joseph F, Davis M, Holmes P, Thekkepay S, Park A, Capehorn M, Taheri S, Aroda VR, Blevins TC, Bode BW, Bressler P, Bristol PE, Cheung D, Bergenstal RM, Fitz-Patrick D, Furlong K, Gorman D, Hollander P, Huffman D, Kwon E, Lipetz RS, Lucas KJ, Pollock J, Rivera-Colon L, Rosenstock J, Salazar HA, Selam JL, Shelmet J, Simon HJ, Soler NG, Sugimoto D, Touger S, Wynne A, Leichter SB, Klein EJ, Kolettis EM, Lynn L, Lane JT, Bays HE, Granda-Rodriguez R, Busch RS, Cannon K, Chang A, Chappel CM, Dow JT, Earl JK, Elinoff V, Farmer MV, Woolley JH, Gonte WS, Klein S, Lane WS, Lang JA, Lerman S, Lubin B, Martin PA, McNeill RE, Mills RE, Murray AV, Myers L, Bao S, Orr R, Powell S, Reed JC, Rhudy J, Saway W, Sofley W, Turner M, Welch M, Wilson J, Zimmerman TS. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA - Journal of the American Medical Association. 2015;314(7):687-699.

74. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L, Investigators NN. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451.

75. le Roux CW, Astrup AV, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X, Hamann A, Barakat A, Blüher M, Linn T, Mölle A, Segner A, Stübler P, Tosch-Sisting R, Pacini F, Santini F, Marchesini G, Rotella CM, Invitti C, Vettor R, Buscemi S, Raya PM, Freijoo FC, de Barbará RG, Carraro R, Bobillo ER, de la Cuesta C, Farsang C, Csaszar A, Zahorska-Markiewicz B, Pupek-Musialik D, Franek E, Ostrowska L, Olszanecka-Glinianowicz M, Lalic N, Micic D, Ludvik B, Paulweber B, Prager R, Scheen A, Hermansen K, Madsbad S, Rissanen A, Nieminen S, Savolainen M, Krempf M, Romon M, Laville M, Marre M, Mira R, Finucane F, Veenendaal A, van Berkum F, Johannsson-Vidarsdóttir S, Van de Walle V, Meesters E, Hjelmesæth J, Klemsdal TO, Kulseng B, Bach-Kliegel B, Laederach K, Villiger L, Golay A, Bilz S, Sathyapalan T, Bain S, Kumar S, Lean MEJ, McGowan B, Rehman T, Wilding J, Wittert G, Caterson I, Proietto J, Prins J, Neto BG, Gross JL, Chacra AR, Halpern A, de Almeida Suplicy H, Chow FCC, Thacker HP, Chadha M, Chandalia H, Unnikrishnan A, Kalra S, Deshpande N, Shunmugavelu M, Deshmukh VC, Maislos M, Lieberman GS, Shimon I, Stern N, Nabriski D, Karnieli E, Shehadeh N, Gonzalez-Galvez G, del Rosario Arechavaleta-Granell M, Ortiz RMV, Franco GM, Gurieva I, Suplotova LA, Troshina E, Ruyatkina LA, Voychik EA, Martsevich S, Startseva MA, Seeber ME, Badat A, Ellis G, Altuntas Y, Guler S, Ulgen E, Delibasi T, Chetty T, Hart R, Janzen J, Labonte I, Lau D, Liutkus J, O'Keefe D, Padwal R, Ransom TPP, Tytus R, Weisnagel SJ, Adler J, Aqua K, Aronoff SL, Bedel GW, Blevins TC, Blumenau J, Brockmyre AP, Call RS, Canadas R, Chaykin LB, Cohen K, Conrow JK, Davis MG, Downey HJ, Drosman SR, Duckor S, Farmer HF, Farrell J, Fehnel S, Finneran MP, Forbes R, Forker A, Fredrick M, Geller SA, Gill S, Glaser L, Greco SN, Greenway FL, Harper W, Herman L, Hoekstra J, Ingebretsen R, Ison R, Jain RK, Kaplan R, Kaster SR, Haase GA, Kerzner B, Kirstein JL, Koltun W, Krieger DR, Lewis CE, Madder R, Marple RN, McDermott EJ, Mello CJ, Miller AB, Mullen J, Nardandrea J, O'Neil P, Pi-Sunyer FX, Pucillo RM, Rhee C, Redrick S, Pardini A, Rothman J, Rubino DM, Sellers G, Smith T, Byars WD, Soufer J, Sussman AM, Patrick K, Schramm EL, Van Cleeff M, Berg SR, Wyatt HR, Simon JA. 3 Years of Liraglutide Versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes: a Randomised, Double-Blind Trial (SCALE Prediabetes and Obesity). The Lancet. 2017;389(10077):1399-1409.

76. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319.

77. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, Committee LS, Investigators LT. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.

78. Victoza (liraglutide 1.8mg) [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2010.

79. Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017;40(7):839-848.

80. Saxenda (liraglutide 3.0mg) [package insert]. Plainsboro, NJ: Novo Nordisk; 2014.

81. Rhythm Pharmaceuticals. Imcivree (setmelanotide) [package insert]. Boston, MA2021.

82. Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, Du L, Chittenden TW, Gulcher JR, Roy S, Fiedorek F, Gottesdiener K, Cohen S, North KE, Schadt EE, Li SD, Chen R, Van Der Ploeg LHT. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. The Journal of Clinical Endocrinology & Metabolism. 2018;103(7):2601-2612.

83. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970.

84. Novo Nordisk. Wegovy (semaglutide 2.4mg) [package insert]. Plainsboro, NJ2021.

85. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155.

86. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989.

87. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. Journal of the American Medical Association. 2021;325(14):1403.

88. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Journal of the American Medical Association. 2021.

89. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.

90. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

91. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206.

92. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022;387(24):2245-2257.

93. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649.

94. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Journal of the American Medical Association. 2022;327(2):138-150.

95. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.

96. Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, Kushner RF, Lingvay I, Burguera B, Gajos G, Horn DB, Hramiak IM, Jastreboff AM, Kokkinos A, Maeng M, Matos A, Tinahones FJ, Lincoff AM, Ryan DH. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. 2024;47(8):1350-1359.

97. Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066.

98. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024.

99. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling A-S, Harrison SA. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021;384(12):1113-1124.

100. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084.

101. Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. Journal of the American College of Cardiology. 2024;84(1):27-40.

102. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176.

103. Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid. 2024;34(4):403-418.

104. Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(9):102834.

105. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins GIP and GLP-1 in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity and Metabolism. 2021;23(S3):5-29.

106. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature Reviews Endocrinology. 2023;19(4):201-216.

107. El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, Wainscott DB, Yang B, Chen A, Wothe D, Coupland C, Tschöp MH, Finan B, D’Alessio DA, Sloop KW, Müller TD, Campbell JE. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. 2023;5(6):945-954.

108. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.

109. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.

110. Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, Leonard S, Jakicic JM. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023;12(4):453-473.

111. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024.

112. Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, Kaplan LM, Fujioka K, Matejkova E, Svacina S, Luzi L, Gnessi L, Navas-Carretero S, Alfredo Martinez J, Still CD, Sannino A, Saponaro C, Demitri C, Urban LE, Leider H, Chiquette E, Ron ES, Zohar Y, Heshmati HM. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring, Md). 2019;27(2):205-216.

113. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633-641.

114. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10(10):1049-1056.

115. Wellbutrin (bupropion hydrochloride) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 1985.

116. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585.

117. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328-341.

118. Hawley SA, Gadalla AE, Olsen GS, Grahame Hardie D. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51(8):2420-2425.

119. Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. 2017(1463-1326 (Electronic)).

120. Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, Cimino I, Yang M, Welsh P, Virtue S, Goldspink DA, Miedzybrodzka EL, Konopka AR, Esponda RR, Huang JTJ, Tung YCL, Rodriguez-Cuenca S, Tomaz RA, Harding HP, Melvin A, Yeo GSH, Preiss D, Vidal-Puig A, Vallier L, Nair KS, Wareham NJ, Ron D, Gribble FM, Reimann F, Sattar N, Savage DB, Allan BB, O’Rahilly S. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(2295):444-448.

121. Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011;60(3):327-334.

122. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes. 2006;55(3):716-724.

123. Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM, Diabetes Prevention Program Research G. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS). Ann Intern Med. 2019;170(10):682-690.

124. Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. Current Atherosclerosis Reports. 2016;18(4):16-16.

125. Glucophage (metformin hydrochloride) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 1995.

126. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010(1):CD002967.

127. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP, Group DPPR. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of clinical endocrinology and metabolism. 2016;101(4):1754-1761.

128. Lutz TA. The role of amylin in the control of energy homeostasis. American journal of physiology Regulatory, integrative and comparative physiology. 2010;298(6):R1475-1484.

129. Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. American journal of physiology Endocrinology and metabolism. 2007;293(2):E620-627.

130. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4):661-668.

131. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of clinical endocrinology and metabolism. 2007;92(8):2977-2983.

132. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-1823.

133. Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183-1187.

134. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, obesity & metabolism. 2014;16(2):159-169.

135. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

136. Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, obesity & metabolism. 2018;20(6):1453-1460.

137. Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018;138(5):458-468.

138. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, Group CPC. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-334.

139. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Investigators D-T. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.

140. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.

141. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020;141(5):407-410.

142. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committees D-HT, Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.

143. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.

144. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, Investigators D-C. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35(2):274-282.

145. Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes, obesity & metabolism. 2020;22 Suppl 1:46-54.

146. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). New England Journal of Medicine. 2020;383(15):1436-1446.

147. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127.

148. Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism. 2023;25(10):2954-2962.

149. Janssen. Invokana (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.; 2013.

150. AstraZeneca. Farxiga (dapagliflozin) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014.

151. Merck. Steglatro (ertugliflozin) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2017.

152. Lilly. Jardiance (empagliflozin) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.

153. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47(3):271-273.

154. Topamax (topiramate) [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.,; 1996.

155. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. Journal of the American Medical Association. 2003;289(14):1820-1825.

156. Gadde KM, Kopping MF, Wagner HR, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Archives of internal medicine. 2012;172(20):1557-1564.

157. Zonegran (zonisamide) [package insert]. Teaneck, NJ: Eisai Inc.; 2000.

158. Myalept [package insert]. Amylin Pharmaceuticals, LLC. Wilmington, DE 19850. Jun 2014.

159. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism. 2015;64(1):146-156.

160. Saunders KH, Igel LI, Shukla AP, Aronne LJ. Drug-induced weight gain: Rethinking our choices. J Fam Pract. 2016;65(11):780-788.

161. Verhaegen A, Van Gaal L. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. 2000.

162. Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, eds. Endotext. South Dartmouth (MA)2000.

163. Igel LI, Kumar RB, Saunders KH, Aronne LJ. Practical Use of Pharmacotherapy for Obesity. Gastroenterology. 2017;152(7):1765-1779.

164. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.

165. Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.

166. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888.

167. Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Network Open. 2021;4(1):e2033457.

168. Tronieri JS, Wadden TA, Walsh OA, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Chao AM. Effects of liraglutide plus phentermine in adults with obesity following 1year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. Metabolism: clinical and experimental. 2019;96:83-91.

169. Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017;40(5):632-639.